Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.64
-0.24 (-4.08%)
Jun 13, 2025, 12:17 PM - Market open
Verastem Revenue
Verastem had revenue of $10.00M in the twelve months ending March 31, 2025. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
25.02
Revenue / Employee
$128,205
Employees
78
Market Cap
309.91M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VSTM News
- 11 days ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - Business Wire
- 16 days ago - Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
- 21 days ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - Business Wire
- 24 days ago - Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - Business Wire
- 4 weeks ago - Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 5 weeks ago - FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - Business Wire
- 5 weeks ago - U.S. FDA approves Verastem's cancer therapy - Reuters
- 6 weeks ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire